Herceptin (trastuzumab) is given every three weeks because the drug stays active in your body long enough to maintain effective levels between doses. At the higher dose used in the three-weekly schedule (6 mg/kg), trastuzumab clears slowly enough that it keeps blocking the HER2 protein on cancer cells throughout the full 21-day cycle. This spacing also aligns with standard chemotherapy cycles, making combined treatment more practical.
How the Drug Stays Active for 21 Days
Trastuzumab is a large antibody protein, and like most antibodies, the body breaks it down slowly. Its half-life (the time it takes for blood levels to drop by half) depends on the dose. At lower doses, the half-life averages around 5.8 days, but at higher doses it stretches considerably longer because the body’s clearance pathways become saturated. In practical terms, a larger dose given less often can maintain the same overall drug exposure as a smaller dose given weekly.
The three-weekly schedule uses this to its advantage. You receive a bigger loading dose at the start (8 mg/kg), which floods the bloodstream and saturates the HER2 targets on cancer cells. Each subsequent dose of 6 mg/kg then tops up blood levels before they drop below the threshold needed to keep HER2 blocked. Pharmacokinetic modeling estimated that steady-state blood levels reach approximately 65 micrograms per milliliter, and it takes about 14 weeks of treatment to get there. Once at steady state, the three-week cycle reliably keeps drug levels in the therapeutic range.
The Two Approved Schedules
Herceptin actually has two FDA-approved dosing schedules: weekly and every three weeks. Which one you’re on depends on your treatment plan and where you are in it.
- Weekly schedule: A loading dose of 4 mg/kg followed by 2 mg/kg each week. This is typically used during the initial chemotherapy phase, when you’re receiving drugs like paclitaxel or docetaxel alongside Herceptin for 12 to 18 weeks.
- Three-weekly schedule: A loading dose of 8 mg/kg followed by 6 mg/kg every 21 days. This is the standard for the longer maintenance phase after chemotherapy ends, and it’s also used for metastatic gastric cancer from the start of treatment.
Many patients start on the weekly schedule during chemo, then switch to every three weeks once that phase wraps up. The three-weekly schedule continues for the remainder of the treatment course, which in adjuvant breast cancer totals about one year overall.
Why Every Three Weeks Is Preferred Long-Term
The shift to a three-weekly schedule after the initial chemotherapy phase is largely about convenience and quality of life. Visiting an infusion center once every three weeks instead of every week means far fewer clinic days, less time away from work or family, and fewer needle sticks over the course of a year. For a treatment that can run 12 months or longer, that difference adds up quickly.
Infusion times also get shorter with time. The very first dose is delivered over about 90 minutes to watch for reactions. If that goes well, later infusions can be shortened to as little as 30 minutes. Combined with less frequent visits, the three-weekly schedule turns what could be 40 or more clinic trips into roughly 14 to 17.
From an effectiveness standpoint, the three-weekly schedule delivers the same total drug exposure as weekly dosing when calculated over time. Both approaches keep enough trastuzumab in the blood to occupy HER2 receptors on tumor cells, which is the mechanism that slows or stops cancer growth.
What Happens if You Miss a Dose
Because trastuzumab levels need to stay above a certain threshold, missing a scheduled infusion by more than one week triggers a protocol adjustment. Rather than simply picking up where you left off at the regular maintenance dose, you’ll receive a full re-loading dose (8 mg/kg for the three-weekly schedule) to quickly bring blood levels back up. Your next maintenance dose then follows 21 days later, resetting the normal cycle.
This re-loading step exists because drug levels can fall below the effective range if too much time passes between infusions. It’s a straightforward fix, but it underscores why sticking to the schedule matters. Each three-week gap is calibrated to the drug’s clearance rate, and stretching it too far risks leaving cancer cells without adequate HER2 blockade.
Side Effects to Be Aware Of
Trastuzumab’s most notable risk is its effect on the heart. In clinical trials, about 2.7% of patients receiving trastuzumab experienced significant cardiac dysfunction, compared to 0% in patients not receiving it. This typically shows up as a drop in how efficiently the heart pumps blood, which is why your care team will monitor heart function with imaging tests at regular intervals throughout treatment.
Most patients tolerate the three-weekly schedule well. Common side effects include fever, chills, or flu-like symptoms during or shortly after the infusion, particularly with the first dose. These tend to become milder with subsequent infusions. The three-weekly schedule doesn’t appear to carry a meaningfully different side effect profile compared to weekly dosing; the total drug exposure over time is comparable, so the risk profile is similar.